A Multicenter Trial of the Efficacy and Safety of a New Formulation of Ibuprofen 800 mg Every 6 Hours in the Management of Postoperative Pain

Last updated: October 1, 2014
Sponsor: Biomendi S.A.U.
Overall Status: Terminated

Phase

3

Condition

Acute Pain

Chronic Pain

Post-surgical Pain

Treatment

N/A

Clinical Study ID

NCT02254525
BIBEC02
  • Ages 18-80
  • All Genders

Study Summary

The purpose of this study is to study the efficacy of intravenous administration of ibuprofen compared to placebo in patients with postoperative pain and evaluate its tolerability and safety profile.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Men or women between 18 and 80 years old.

  2. Being scheduled for elective single surgical site orthopaedic surgery (hip or kneejoint replacement, corsed ligaments, column or shoulder surgery), or abdominal surgery (inguinal hernia, cholecystectomy, eventration or hiatus hernia)

  3. Being scheduled for general anaesthesia or regional anesthesia without regionalanalgesia after surgery.

  4. Having anticipated need for postoperative narcotic analgesia administered by patientcontrolled analgesia (PCA).

  5. Expected to stay at the hospital for at least 24 h.

  6. Providing written informed consent for participating in this study.

Exclusion

Exclusion Criteria:

  1. Use of NSAID within 12 hours prior to the first planned dose.

  2. Taking oral anticoagulants, lithium, combination of ACE inhibitors, furosemide oraspirin.

  3. Anaemia (haemoglobin <10 g/dl) and/or history or evidence of asthma or heart failure.

  4. History of allergy or hypersensitivity to any component of IV ibuprofen, aspirin oraspirin related products, NSAID or COX-2 inhibitors.

  5. Pregnant or nursing.

  6. Weight less than 40 kg.

  7. History of severe head trauma that required hospitalization, intracranial surgery orstroke within the previous 30 days, or any history of intracerebral arteriovenousmalformation, cerebral aneurism or CNS mass lesion.

  8. History of congenital bleeding diathesis or any active clinically significant bleedingor underlying platelet dysfunction.

  9. Gastrointestinal bleeding that required medical intervention.

  10. Platelet count less than 80.000 determined within the 28 days prior to surgery.

  11. Pre-existing dependence on narcotics or receiving chronic treatment with opioids.

  12. Severe renal failure (calculated creatinine clearance < 60 ml/min).

  13. Liver failure, ALAT or ASAT >3 times upper limit of normality, or bilirubin >2 g/dl.

  14. Diagnosed of Bowel Inflammatory Disease.

  15. Not able to understand the requirements of the study, or to abide by the studyrestrictions or to return for the required assessments.

Study Design

Total Participants: 231
Study Start date:
May 01, 2012
Estimated Completion Date:
July 31, 2014

Study Description

This is a phase III, national, multicenter, randomized, double-blind, parallel groups, and placebo-controlled.

Patients will be randomized to receive either ibuprofen or placebo. Stratified randomization will be used to assign eligible patients to a stratum according to type of surgery and centre. Randomization sequence will be generated in the coordinating centre.

Blinding of the patient and study personnel evaluating response will be warranted by adequate drug labelling.

All patients will receive morphine administered by patient controlled analgesia (PCA) following a similar schedule in all centres: 1 mg bolus dose with a close time of 5 min and a maximum of 10 mg in an hour and a maximum of 30 mg in 4 hours.

Connect with a study center

  • Hospital de Móstoles

    Móstoles, Madrid 28935
    Spain

    Site Not Available

  • Hospital Xeral Cíes de Vigo

    Vigo, Pontevedra 15781
    Spain

    Site Not Available

  • Hospital de Cruces

    Barakaldo, Vizcaya 48903
    Spain

    Site Not Available

  • Complejo Hospitalario Universitario de A Coruña

    La Coruña, 15001
    Spain

    Site Not Available

  • Hospital Arnau de Vilanova de Lleida

    Lleida, 25198
    Spain

    Site Not Available

  • Fundación Jiménez Díaz

    Madrid, 28040
    Spain

    Site Not Available

  • Hospital 12 de Octubre

    Madrid, 28041
    Spain

    Site Not Available

  • Hospital La Princesa

    Madrid, 28006
    Spain

    Site Not Available

  • Hospital de Montepríncipe

    Madrid, 28660
    Spain

    Site Not Available

  • Clínica Universitaria de Navarra

    Pamplona, 31008
    Spain

    Site Not Available

  • Hospital Virgen de la Salud

    Toledo, 45005
    Spain

    Site Not Available

  • Hospital La Fe

    Valencia, 46026
    Spain

    Site Not Available

  • Hospital Clínico de Valladolid

    Valladolid, 47005
    Spain

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.